GoAI
Get started
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc.

LENZ

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.68

+$0.02 · +0.43%

Aug 21, 4:00 PM ET

Pre-market

$4.68

$0.00 · 0.00%

Aug 24, 5:17 AM ET

LENZ company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

58

Fair Value

Momentum

21

Weakening

Sentiment

63

Bullish

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Evert Schimmelpennink
Listed since
Jun 25, 2021
Employees
152

Market position

Day range

Current $4.68

52-week range

Current $4.68

Open
$4.76
Previous close
$4.66
Volume
475.32K
0.55× average
Average volume
872.08K
Average daily volume
Market cap
146.74M USD
Beta
1.63
Market reference 1
50-day average
$5.4747
-14.52% below average
200-day average
$12.4974
-62.55% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
436.65M USD
P/E (TTM)
-1.14×
P/B (TTM)
0.67×
P/S (TTM)
6.83×
EV / EBITDA
-5.37×
Earnings yield
-17.81%
Free cash flow yield
-15.18%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
90.14%
Operating margin
-631.70%
Net margin
-586.74%
Return on equity
-28.88%
Return on assets
-26.85%
Return on invested capital
-31.96%

Financial health

Debt / equity
0×
Current ratio
14.23×
Altman Z-score
2.73
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends158%-73%-304%-535%Gross margin, FY2022: 100.00%Gross margin, FY2025: 96.31%Operating margin, FY2022: -69.89%Operating margin, FY2025: -477.46%Net margin, FY2022: -72.07%Net margin, FY2025: -430.25%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2025 96.31%. Operating margin FY2022 -69.89%. Operating margin FY2025 -477.46%. Net margin FY2022 -72.07%. Net margin FY2025 -430.25%.

Income trends

Revenue

19.09M USD+27.25%

Operating income

−91.14M USD-55.50%

Net income

−82.13M USD-65.02%
Income trends across reported periods30.11M USD−13.98M USD−58.07M USD−102.16M USDRevenue, FY2022: 15M USDRevenue, FY2025: 19.09M USDOperating income, FY2021: −60.44M USDOperating income, FY2022: −10.48M USDOperating income, FY2023: −72.43M USDOperating income, FY2024: −58.61M USDOperating income, FY2025: −91.14M USDNet income, FY2021: −70.76M USDNet income, FY2022: −10.81M USDNet income, FY2023: −69.97M USDNet income, FY2024: −49.77M USDNet income, FY2025: −82.13M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 15M USD. Revenue FY2025 19.09M USD. Operating income FY2021 −60.44M USD. Operating income FY2022 −10.48M USD. Operating income FY2023 −72.43M USD. Operating income FY2024 −58.61M USD. Operating income FY2025 −91.14M USD. Net income FY2021 −70.76M USD. Net income FY2022 −10.81M USD. Net income FY2023 −69.97M USD. Net income FY2024 −49.77M USD. Net income FY2025 −82.13M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue19.09M USD——15M USD—
Cost of goods sold705K USD58K USD——734K USD
Gross profit18.38M USD−58K USD—15M USD−734K USD
Research and development18.67M USD29.8M USD59.5M USD21.13M USD37.93M USD
Selling, general, and administrative90.85M USD28.75M USD12.93M USD4.36M USD21.78M USD
Operating expenses109.52M USD58.55M USD72.43M USD25.48M USD59.71M USD
Interest income9.76M USD8.55M USD2.19M USD——
Depreciation and amortization287K USD58K USD15K USD8K USD734K USD
Operating income−91.14M USD−58.61M USD−72.43M USD−10.48M USD−60.44M USD
Net income−82.13M USD−49.77M USD−69.97M USD−10.81M USD−70.76M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-47.46%
11 comparable reports
Latest EPS result
-1.02
Estimate -1.05 · Beat by 2.86%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.36-0.7-1.05-1.39Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual -0.46, estimate -0.42, surprise -9.52%, Miss. Q2 2025, reported May 7, 2025: actual -0.53, estimate -0.55, surprise +3.64%, Beat. Q3 2025, reported Jul 30, 2025: actual -0.53, estimate -0.58, surprise +8.62%, Beat. Q4 2025, reported Nov 5, 2025: actual -0.59, estimate -0.67, surprise +11.94%, Beat. Q1 2026, reported Mar 24, 2026: actual -1.16, estimate -0.91, surprise -27.47%, Miss. Q2 2026, reported May 11, 2026: actual -1.32, estimate -1.1, surprise -20.00%, Miss. Q3 2026, reported Aug 11, 2026: actual -1.02, estimate -1.05, surprise +2.86%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -1.02, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates13.44M9.16M4.89M607.14KQ2 '25EstimateQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported May 7, 2025: actual —, estimate 714.29K USD, surprise —, Comparison unavailable. Q3 2025, reported Jul 30, 2025: actual 5M USD, estimate 714.29K USD, surprise +600.00%, Beat. Q4 2025, reported Nov 5, 2025: actual 12.5M USD, estimate 3.09M USD, surprise +304.78%, Beat. Q1 2026, reported Mar 24, 2026: actual 1.59M USD, estimate 3.08M USD, surprise -48.50%, Miss. Q2 2026, reported May 11, 2026: actual 1.9M USD, estimate 1.76M USD, surprise +8.08%, Beat. Q3 2026, reported Aug 11, 2026: actual 5.49M USD, estimate 2.38M USD, surprise +130.76%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 4.49M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.00

49.57% upside
Past 12 months12-month forecastHigh $7.00Average $7.00Low $7.00

Rating distribution

5 ratings
Strong buy00%
Buy480%
Hold120%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
B of A SecuritiesmaintainBuy

LENZ news

seekingalpha.com

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July…

Read source
zacks.com

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.53 per share a year ago.

Read source
globenewswire.com

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple monthly packs since…

Read source
globenewswire.com

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution)…

Read source
zacks.com

Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline

LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read source

Corporate actions

Corporate action history

Dividend

Ex-dividend Mar 22, 2024

$1.03

Weekly

Record Mar 18, 2024

Dividend

Ex-dividend Mar 15, 2024

$1.03

Weekly

LENZ peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LENZ

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
4.34M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
2.47M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.34M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.09M
Weight
0.02%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
946.51K
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
798.59K
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
603.3K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
483.04K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research LENZ

research.disclaimer